相关实验视频

Updated: Feb 19, 2026

Single-Port Robotic-assisted Transaxillary Breast-conserving Surgery: A Prospective, Single-arm, Non-randomized Phase IIa Clinical Trial

Single-Port Robotic-assisted Transaxillary Breast-conserving Surgery: A Prospective, Single-arm, Non-randomized Phase IIa Clinical Trial

Published on: August 19, 2025

多学科诊所是否会影响乳腺保护疗法的发生率?

Tara Chandran¹, Jamie L Wager^1,2, Karam Obeid¹

¹Division of Breast Surgical Oncology, Department of Surgery, University of Kansas Medical Center, Kansas City, KS, USA.

Annals of surgical oncology

|February 17, 2026

概括

包括放射瘤学家 (RO) 在内的多学科诊所 (MDC) 显著增加了乳腺保护疗法 (BCT) 率. 将RO整合到MDC咨询中可以增强符合条件的乳腺癌患者的患者教育和共享决策.

科学领域:

在瘤学瘤学.
手术瘤学手术瘤学
辐射瘤学辐射瘤学

背景情况:

影响乳腺保护疗法 (BCT) 率的因素已知,但多学科诊所 (MDC) 的影响仍然未经记录.
这项研究调查了乳腺癌患者的MDC组成和BCT率之间的关联.

研究的目的:

确定多学科诊所 (MDC) 咨询,特别是包括外科和放射瘤学家在内的咨询,是否会影响乳腺保护疗法 (BCT) 率.
在不同的MDC配置和仅BSO咨询中比较BCT率.

主要方法:

对2023年乳腺癌0-III期患者的回顾性图表审查,提供BCT.
根据初始咨询,患者被分为四个队列:三方提供者MDC (BSO,MO,RO),MDC中的BSO+RO,MDC中的BSO+MO和仅BSO.
统计分析 (威尔科克森排名和值,奇方形/费舍尔精确测试) 比较BCT与乳腺切除率.

主要成果:

最初的咨询类型显著影响了BCT率 (p = 0.015).
在三家供应商的MDC (89%) 和BSO+RO在MDC (86%) 中观察到最高的BCT率.
在MDC (78%) 和BSO单独 (77%) 队列中,BSO+MO的BCT率较低,这凸显了RO纳入的重要性.

结论:

包括放射瘤学家 (RO) 在内的多学科诊所 (MDC) 咨询与更高的乳腺保护疗法 (BCT) 率有关.
在乳腺外科瘤学 (BSO) 与乳腺外科瘤学 (RO) 结合的MDCs的更广泛采用可能会增加BCT的接受率.
加强患者教育和MDC内部的共享决策有助于改善BCT结果.

更多相关视频

Proton Therapy Delivery and Its Clinical Application in Select Solid Tumor Malignancies

Proton Therapy Delivery and Its Clinical Application in Select Solid Tumor Malignancies

Published on: February 6, 2019

Endoscopic Bilateral Nipple-sparing Mastectomy via a Single Axillary Incision with Immediate Pre-pectoral Implant-based Breast Reconstruction

Endoscopic Bilateral Nipple-sparing Mastectomy via a Single Axillary Incision with Immediate Pre-pectoral Implant-based Breast Reconstruction

Published on: May 17, 2024

相关概念视频

Treatment Resistant Cancers

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...